Zuclopenthixol- a typical antipsychotic drug of the thioxanthene class.

Zuclopenthixol, also known as zuclopentixol, is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1962 by Lundbeck. It is the cis-isomer of clopenthixol.

Zuclopenthixol- a typical antipsychotic drug of the thioxanthene class.

Zuclopenthixol; Clopixol; Cisordinol; Zuclopentixol; Zuclopenthixolum

Clopixol Acuphase, Clopixol Depot

2-(4-{3-[(9Z)-2-chloro-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol

Zuclopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. Zuclopenthixol is a typical antipsychotic neuroleptic drug of the thioxanthene class. It mainly acts by antagonism of D1 and D2 dopamine receptors. Zuclopenthixol also has high affinity for alpha1-adrenergic and 5-HT2 receptors. 

20-30 mg daily in divided doses. Up to 50mg

Used in the management of acute psychoses such as mania or schizophrenia.

Neuroleptic malignant syndrome, blood dyscrasias. Drowsiness, tachycardia, blurred vision, nausea, headache, dizziness, excitement, hyperprolactinaemia, postural hypotension, sexual dysfunction, ECG changes (prolongation of QT interval and T wave changes), hyperthermia. Extra pyramidal symptoms may occur, especially during the early phase of treatment; urinary frequency or incontinence; tardive dyskinesia.

• It enhances the effects of barbiturates, the sedative effects of alcohol, and other CNS depressants.
• Zuclopenthixol reduces the antihypertensive effect of guanethidine.
• Concomitant use of metoclopramide and piperazine with zuclopenthixol increases the risk of extrapyramidal symptoms.
• Increased risk of severe neurotoxicity with sibutramine and lithium.
•  Increased anticholinergic side effects with drugs with anticholinergic properties.
• Antagonises effect of apomorphine, levodopa and other dopamine agonists.
•  Increased risk of blood dyscrasias with clozapine.
• Increased risks of arrhythmias with drugs that prolong QT interval, erythromycin or cause electrolyte disturbances e.g. thiazide diuretics.

Hypersensitivity. Comatose states e.g. alcohol, barbiturate and opiate intoxications; porphyria. Children.

Store below 25°C.

Molecular weight

400.965

Molecular formula

C22H25ClN2OS

CAS number

53772-83-1

Precautions

Hepatic and renal impairment, heart disease, recent acute MI, arrhythmias, significant bradycardia (<50 beats/min), severe respiratory disease, acute angle glaucoma, epilepsy, Parkinson's disease, hypothyroidism, prostatic hypertrophy, hyperthyroidism, myasthenia gravis, phaeochromocytoma. Patients at risk of stroke and QT interval prolongation. Avoid abrupt withdrawal. Ability to drive a car or operate machinery may be impaired.